Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ford

Showing results (1171-1180 of 1,228) with videos related to

Pageof 123
Sort By:
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
Plos Pathogens|August 25, 2018
Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replicationKrystelle Nganou-Makamdop, James M Billingsley, Zachary Yaffe, et al.
Cell Reports|December 9, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
The Journal of Biological Chemistry|April 24, 2014
Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migrationAaron B Krueger, David J Drasin, Wendy A Lea, et al.
Neurology|September 5, 2020
Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathyAndria L Ford, Victoria W Chin, Slim Fellah, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 19, 2017
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft RejectionS C Kim, W Wakwe, L B Higginbotham, et al.
JCI Insight|April 14, 2022
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosisCory Wilson, Tinne Cj Mertens, Pooja Shivshankar, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Cell Reports|January 23, 2026
Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemiaLiam Clayfield, Divya Malik, Jessica Whittle, et al.
Pageof 123

Showing results (1171-1180 of 1,228) with videos related to

Sort By:
Pageof 123
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
Plos Pathogens|August 25, 2018
Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replicationKrystelle Nganou-Makamdop, James M Billingsley, Zachary Yaffe, et al.
Cell Reports|December 9, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
The Journal of Biological Chemistry|April 24, 2014
Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migrationAaron B Krueger, David J Drasin, Wendy A Lea, et al.
Neurology|September 5, 2020
Lesion evolution and neurodegeneration in RVCL-S: A monogenic microvasculopathyAndria L Ford, Victoria W Chin, Slim Fellah, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 19, 2017
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft RejectionS C Kim, W Wakwe, L B Higginbotham, et al.
JCI Insight|April 14, 2022
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosisCory Wilson, Tinne Cj Mertens, Pooja Shivshankar, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Cell Reports|January 23, 2026
Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemiaLiam Clayfield, Divya Malik, Jessica Whittle, et al.
Pageof 123